Company ProfilePremium

Meda Pharmaceuticals

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Meda Pharmaceuticals - Healthcare showcase

Year Founded & Workforce

1954

4,600 Employees

Industry

Healthcare

Services

Allergic Rhinitis
M

Meda Pharmaceuticals Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Meda Pharmaceuticals Overview

Company Headquarters: Dubai, UAE

Founded: 1954

Workforce: ~4,600

Company Working: Meda Pharmaceuticals operates as a subsidiary of Mylan NV and is actively involved in the production, distribution, and marketing of prescription and OTC pharmaceutical products. The company operates through the following business segments— allergy, pain management, gastrointestinal, urology, cardio and CNS, dermatology, and OTC. It has a direct presence in 60 countries and it also offers its products through distributors in more than 150 countries including Australia, China, Italy, South Africa, the UK, and the UAE. More than 50% of its revenue comes from respiratory, dermatology, and pain and inflammation therapeutic areas

Strategy

Meda Pharmaceuticals focuses on acquisitions to strengthen core areas of the product portfolio and strategic arrangements with other players to expand geographic boundaries. Meda Pharmaceuticals mainly concentrates on the manufacturing of products related to respiratory, dermatology, and pain and inflammation therapeutic areas and for generating maximum revenue. It mainly operates in international markets, but it also generates a significant amount of revenue from the domestic market.

Company Snapshot

$10,967.1M

Revenue

4,600

Employees

1954

Founded

Dubai, UAE

Headquarters

SWOT Analysis

Strengths

  • Involved in mergers & acquisitions
  • Offers an extensive range of dosage forms and delivery systems
  • Robust worldwide commercial presence

Weaknesses

  • Limited products

Opportunities

  • Collaborations to develop innovative medicines

Threats

  • Pricing pressures may affect the company's future revenues

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
–AcquisitionMylan NV acquired Meda, thus, expanding its franchises in various therapeutic areas.

Product Offering

  • Meda Pharmaceuticals
    • Allergic Rhinitis

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 10,967.1 Mn in 2016 to USD 11,268.7 Mn in 2018.
Meda Pharmaceuticals — By Business Segment
Series (USD Mn)201620172018
Sales10,967.111,76011,268.7
R&D Expenditure826.8783.3704.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.